PTH1R and hypoparathyroidism: This would extend to the orally available small molecule PTHR1 agonist, PCO371, which has been shown to restore sCa and lower sPi levels in TPTX rats,17 and is currently being evaluated in an early‐stage clinical trial for hypoparathyroidism.